Shares of Alkermes PLC (NASDAQ:ALKS) have been assigned a consensus recommendation of “Hold” from the fifteen ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $63.40.
A number of equities research analysts have recently issued reports on the stock. Barclays set a $50.00 price target on shares of Alkermes and gave the company a “hold” rating in a research report on Thursday, October 26th. ValuEngine downgraded shares of Alkermes from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. J P Morgan Chase & Co set a $78.00 price target on shares of Alkermes and gave the company a “buy” rating in a research report on Friday, October 27th. Citigroup set a $62.00 price target on shares of Alkermes and gave the company a “hold” rating in a research report on Thursday, October 26th. Finally, Jefferies Group set a $69.00 price target on shares of Alkermes and gave the company a “buy” rating in a research report on Friday, August 25th.
In other Alkermes news, SVP James M. Frates sold 20,932 shares of Alkermes stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $50.51, for a total value of $1,057,275.32. Following the completion of the sale, the senior vice president now directly owns 164,971 shares of the company’s stock, valued at approximately $8,332,685.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of Alkermes stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $50.64, for a total transaction of $75,960.00. The disclosure for this sale can be found here. Insiders have sold a total of 109,364 shares of company stock valued at $5,355,310 over the last 90 days. Insiders own 5.34% of the company’s stock.
Alkermes (NASDAQ ALKS) traded up $0.28 during mid-day trading on Friday, hitting $51.84. 943,695 shares of the stock were exchanged, compared to its average volume of 848,249. Alkermes has a 52 week low of $46.42 and a 52 week high of $63.40. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72.
Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same period last year, the firm earned ($0.09) EPS. The company’s revenue for the quarter was up 20.6% on a year-over-year basis. analysts forecast that Alkermes will post -0.59 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Alkermes PLC (ALKS) Given Average Rating of “Hold” by Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/15/alkermes-plc-alks-given-average-rating-of-hold-by-analysts.html.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.